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Abstract
Background: Anaplastic lymphoma kinase (ALK) is a key oncogenic driver in lung adenocarcinoma patients and its
fusion proteins are routinely assessed. The microfluidic tissue processor (MTP) device is based on a chip-confined
low-volume technology allowing for rapid immunohistochemistry/immunofluorescence (IHC/IF) stainings of
formalin-fixed paraffin-embedded (FFPE) or frozen tissue samples.
Methods: A novel ALK IF protocol was developed for the MTP device using the primary mouse anti-human ALK
antibody clone 5A4. FFPE tumor whole sections from 14 resected lung adenocarcinoma patients documented to
be ALK positive (ALK+) by automated chromogenic IHC and/or FISH were used. MTP-derived IF immunoreactivity
was measured by computerized analysis of digitalized images on individual frames of tumor epithelia and
surrounding stroma, using an ImageJ plug-in.
Results: The 5A4 antibody yielded saturated immunoreactivity at an incubation time of 4 min on a titration curve
ranging from 2 to 32 min. Total staining time on the MTP device was 18 min including secondary IgG Alexa Fluor
647. MTP-based ALK IF confirmed all 12 cases; with epithelial signal above stromal staining based on computerized
pixel-based measurement. MTP-IF (mean intensity levels 458 to 1301) and chromogenic IHC (H-score 120 to 300)
showed an equal range of variation of 2.8 and 2.5 folds, respectively, and a trend for direct correlation (p-value 0.
051).
Conclusion: The newly developed protocol for immunofluorescent detection of ALK protein with the MTP device
confirms chromogenic IHC results on FFPE lung adenocarcinoma specimens. MTP-based IF is fast and reliable. We
foresee this study to be a first step opening the road for further realization of microfluidic-based assays for rapid
simultaneous detection of targetable oncogenic and immune-system related markers in their topographical context
to investigate tumour heterogeneity and micro-environmental interactions.
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Background
Rearrangement of the anaplastic lymphoma kinase (ALK)
gene is an oncogenic driver event typically occurring in
young non-smokers suffering from a KRAS/EGFR
wild-type lung adenocarcinoma [1, 2]. A paracentric inver-
sion within the ALK gene on chromosome 2p23 fuses with
the EML4 gene or other partners. This chromosomal
rearrangement results in cytosolic expression of an onco-
genic fusion protein, which are targeted by ALK tyrosine
kinase inhibitors (TKI), such as crizotinib and lorlatinib.
Nevertheless, TKI resistance can occur via development
of ALK mutations. The ALK resistance mutation L1198F
induced by lorlatinib, however resensitize tumor cells to
crizotinib [3]. Thus, a suitable sequence of targeted and
classical chemotherapy may result in long lasting patient
survival.
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For the prescription of such regimens, the reliable as-
sessment of ALK protein expression and its alteration on
sequential tumor biopsies together with corresponding
genomic data is of high importance. The four main
methods for ALK assessment include chromogenic immu-
nohistochemistry (IHC), fluorescence in-situ hybridization
(FISH), reverse transcriptase polymerase chain reaction
(RT-PCR) and next generation sequencing (NGS). The
ALK status is routinely assessed in diagnostic surgical
pathology by either or a combination of the four methods.
Yet, there is no international gold standard for the best
assay as all four methods have their respective pros and
cons in terms of pre- and analytical process turnaround
time, accuracy and cost [4, 5]. Regarding IHC, ALK rear-
rangements are detected regardless of variant and fusion
partner. Despite the initial poor performances of ALK on
lung adenocarcinoma, immunohistochemistry is currently
considered reliable and cheap, due to employment of
signal amplification system and optimized anti-ALK
antibodies, such as clone 5A4 (Novocastra) or D5F3
(Ventana), with the latter being approved by FDA (Food
and Drug Administration) as companion diagnostic test
for ALK rearrangements [6].
Microfluidic-based IHC/IF using devices such as the
microfluidic tissue processor (MTP) enhances quality
and reproducibility of immunoreactivity [7]. The MTP
creates a 100 μm high incubation chamber above the tis-
sue covered by a microfluidic chip. Fast fluidic exchange
(FFEX) and border gaskets allow for low incubation
times due to rapid paratope-epitope interaction and
homogenous staining across the zone of confinement
with sharp edges. Using this technology, a better reparti-
tion of HER2 negative versus positive breast carcinomas
was achieved, resulting in a 90% decrease of ambiguous
results. Furthermore, the level of HER2 protein expres-
sion, as continuously quantified using microfluidic preci-
sion IF, predicted the number of HER2 gene copies
obtained from FISH [8].
Immunofluorescence is a valid and in e.g. nephron-path-
ology widely used alternative method to immunohisto-
chemistry with the advantage that a 2-layered protocol of
primary and labelled secondary antibody is often sufficient
to obtain good signal-to-noise ratio [9]. IHC usually re-
quires further amplification steps including hapten linkers
and multimers. IF markers can also be more easily
multiplexed by the tyramide signal amplification (TSA)
technology [10], allowing for parallel assessment of diag-
nostic, oncogenic and immune system-related markers in
respective topographic context.
In this study, we have developed an ALK immuno-
fluorescence protocol for the MTP device to be
performed on FFPE cancer tissue section. Except pre-
treatment including deparaffinization, hydration and
antigen retrieval, all incubation steps were performed
on-chip within the MTP device. We used whole tumor
sections from surgically resected lung adenocarcinoma
patients documented to be ALK+ by chromogenic IHC
and/or FISH. MTP-derived IF immunoreactivity was
measured by computerized analysis of digitalized images
on individual frames of tumor epithelia and surrounding
stroma.
Methods
Patient tumor tissues
Whole section cuts of formalin-fixed, paraffin-embedded
(FFPE) tumor tissue of 14 surgically resected lung adeno-
carcinoma patients of the University Hospital Zurich were
used. One patient (Case N°11) was represented by two
samples. In total, 15 surgical specimens were analyzed.
Three specimens (Case N°12, 13 and 14) were used for
protocol evaluation. The elaborated protocol was applied
to the series of 12 other samples. As control for
ALK-negative samples, we included a tissue microarray
(TMA) of 196 surgically resected non-small cell lung car-
cinoma (NSCLC) patients. The Ethical Commission of the
Canton of Zurich approved the study under reference
number KEK ZH-Nr. 29–2009/14.
Blocking solutions, primary antibodies and detection
systems used for the MTP-IF
To determine the optimal blocking solution the follo-
wing reagent were tested: bovine serum albumin (BSA)
1% (Life Technologies), horse serum 2.5% (Vector
Laboratories), Top Block (Lubioscience) and Sudan
Black B (Sigma-Aldrich).
Mouse anti-human ALK antibody clone 5A4 (Novo-
castra) was used with a dilution of 1/10 in PBS-Tween
(PBST) 0.05% (Fischer Scientific). Mouse anti-human
pan-cytokeratin (pan-CK) antibody cocktail AE1/AE3
(Dako) was diluted 1/100.
Reagents used for the detection step included the goat
anti-mouse IgG (H + L) highly cross-adsorbed Alexa
Fluor 647 (Life Technologies, 1/40), ImmPRESS system
with horseradish peroxidase (HRP)-coupled secondary
antibody (Vector Laboratories, ready-to-use) and tyra-
mide signal amplification (TSA) kit with Alexa Fluor 647
labelled tyramide diluted 1/100 in amplification buffer
according to manufacturer recommendations (Life
Technologies).
For nuclear counterstaining, DAPI was included in
the SlowFade Gold Antifade mounting solution (Life
Technologies, RTU).
Tissue slide pre-processing for MTP-IF
Two μm thick FFPE tumor whole sections were mounted
on glass slides and manually (OFF-chip) de-paraffinized by
heating at 65 °C for 10 min followed by 10 min incubation
with dewaxing solution (Histoclear, National Diagnostic);
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after being rehydrated with decreasing concentrations of
ethanol (100, 95, 70 and 40% v/v, Fischer Chemical) down
to tap water, slides underwent heat-induced antigen re-
trieval step in TRIS/EDTA solution pH 9 (Dako) at 95 °C
for 30 min. Slides were cooled-down for 20 min in the anti-
gen retrieval solution, washed and kept in PBS until the
staining process with the microfluidic device started.
Microfluidic setup
Glass slides were inserted into the MTP device, which
contains a clamping system that interfaces the microflui-
dic chip with the tissue sample via an elastomeric gasket,
forming a chamber of reaction of 100 μm height. Re-
agents were sequentially delivered into the chamber, in-
cubated and washed over the surface of the tissue cuts
on a one-second time resolution, as previously described
[7] and detailed in Fig. 1b. The reagent delivery system
(RDS) consisted of a set of valves used to deliver re-
agents from pressurized reservoirs of 50 mL and 1.5 mL
to the reaction chamber. The microfluidic design allows
for rapid paratope-epitope interactions, thus short
incubation times are possible for immuno-stainings. A
graphical user interface installed in a computer was used
to control all protocol steps.
Immunofluorescence staining on the MTP device
For direct pan-CK IF, both primary and secondary anti-
bodies (IgGAF647) were incubated for 4 min each; other
protocol steps were as in Fig. 1c. Total duration of the
staining was 10 min.
Detailed protocol and total staining time for direct
ALK IF using the fluorophore-conjugated secondary
antibody (IgGAF647) are shown in Fig. 1c.
For TSA mediated ALK indirect IF, the HRP-conjugated
secondary antibody was incubated for 8 min, followed by
fluorescently labelled tyramide incubation for 2 min.
Other protocol steps were as detailed in Fig. 1c.
Negative controls were done by replacing the primary
antibody with the antibody diluent PBST 0.05%; all other
steps of the negative controls correspond to the same
staining conditions of the experiment.
ALK chromogenic IHC staining and scoring
Two μm thick sections of representative tumor blocks
were used. The Refine 30/30 HRP protocol was per-
formed on a Leica Bond-Max automated IHC platform
as following: mounted tissue cuts were dewaxed in a
60 °C oven, rehydrated and boiled for 30 min for heat
induced epitope retrieval (HIER) at pH 8 Tris-buffered
EDTA. Primary antibody 5A4 was diluted 1/10 and incu-
bated for 30 min at room temperature (RT). Thereafter,
the Refine post-primary antibody linker was applied for
15 min at RT, followed by the Refine polymer coupled to
HRP for another 15 min at RT. Diaminobenzidine
(DAB) was incubated for 4 min, followed by hematoxylin
for 15 min. Chromogenic immunoreactivity was
H-scored, whereby whole section tumor areas with
semi-quantitative intensities 0, 1, 2 or 3 were multiplied
by individual frequencies of stained cells and then
summed up (range 0 to 300). As previously described in
the European Thoracic Oncology Platform (ETOP) ALK
001 study, a threshold H-score value higher than 120
was thereafter used to define ALK positivity [11, 12].
ALK fluorescent in-situ hybridization
Four μm thick sections were incubated with a dual color
break apart FISH probe for chromosome 2p23 (LSI
3’-ALK Spectrum-Orange and 5’-ALK Spectrum-Green,
Vysis/Abbott Molecular) according to the manufacturer’s
protocol. For each case, 100 non-overlapping nuclei were
evaluated using a fluorescence microscope (Zeiss
Axioskop) with a 100-fold magnification oil objective.
Z-stacks of 20 images with 0.5 μm step distance were
merged. Positive ALK FISH was defined as > 15% cells
with either break-apart or isolated 3′ signals. Isolated
5′ signals were considered negative.
Image acquisition
The brightfield images of the chromogenic ALK IHC
stainings were digitalized on a NanoZoomer Digital
Pathology scanner (Hamamatsu, Japan). For IF we used
a Zeiss AxioImager M2 m microscope and an Olympus
slide scanner VS120-L100. Each image was taken in both
DAPI (Alexa350) and Cy5 (Alexa647) channels. For all
images within a figure, the same parameters of acquisi-
tion, such as filter set, exposure time, and filter inten-
sities were used.
Image analysis
Image quantification was done using custom written
ImageJ macros. For quantification of the IF signal, 25
representative regions of interest (ROI) were selected
both on tumor epithelia and on stroma areas. For the
tumor epithelia ROIs, which contain both ALK positive
and negative areas, the pixels containing positive signals
were selected in ImageJ by the Huang automatic thresh-
olding before recording the mean fluorescence intensity.
For the stroma areas, where the un-specific signal is re-
ported to appear is various structures, the mean fluores-
cence intensity of whole ROI was recorded, independently
of the expression level and cell type to include fluorescent
signal of any origin. The average signal and corresponding
standard deviation for tumor epithelia and stroma areas
were calculated by averaging the mean intensities from all
25 ROIs.
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Statistical analysis
MTP-derived IF values were correlated with chromo-
genic IHC and break-apart FISH using the Kendall’s
tau-b test. A p-value of ≤0.05 was considered significant.
Results
Determination of optimal blocking solution and detection
system for the MTP-based IF
A schematic depiction of the MTP device with its work-
ing principle is shown in Fig. 1a-b. The tissue slides
pre-processing and staining protocol steps for the MTP
device are shown in Fig. 1c.
Different blocking solutions were tested (Additional file 1:
Figure S1). The optimum blocking solution allowing for a
good specific signal with minimal non-specific back-
ground turned out to be 2.5% horse serum. Regarding the
detection system, two methods were tested: fluorophore-
conjugated secondary antibody IgGAF647 versus tyramide
signal amplification HRP-TSAAF647 (Additional file 1:
Figure S2). Both methods resulted in strong and fast ALK
detection. However, we inferred that the enzyme-based
approach has less controlled reaction kinetics and might
cause non-linearity. Therefore, the IgGAF647 secondary
antibody was further used due to the aim of performing
Fig. 1 Working principle of the microfluidic tissue processor (MTP) and detailed time protocols. a-b The MTP device is based on a pressure-driven
system, which controls the delivery of the reagents from reservoirs of either 1.5 or 50 mL. Reagents are driven to the tissue slide by passing
through the reagent delivery chip (RDC) and the microfluidic tissue processor chip (MTP). The MTP chip is placed on top of the tissue section,
resulting in the formation of a thin closed reaction chamber. This allows for confined epitope-antibody interaction. The exchange of reagents is
done in a timeframe of 1 s, following the principle of the fast-fluidic exchange technology (FFEX). Thereafter, reagents are delivered into the
waste. The clamping of the slide and the protocols details are defined via a user interface connected to the system. c The tissue slide pre-
processing was performed manually (OFF chip) and included (i) dewaxing for 10 min at 65 °C followed by 10 min incubation with dewaxing
solution, (ii) rehydration with decreasing concentrations of ethanol down to tap water, (iii) heat-induced antigen retrieval with TRIS/EDTA pH 9 at
95 °C for 30 min and (iv) cool-down for 20 min. The direct ALK IF staining was performed on the microfluidic device (ON chip) by using the
primary antibody mouse anti-human ALK (Novocastra, clone 5A4) and a fluorescently-labelled secondary anti-mouse IgG antibody (Alexa Fluor
647). The blocking solution was 2.5% horse serum. DAPI was included in the mounting solution for counterstaining
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ALK quantification. Further, we evaluated the border of
confinement delimitated by the gasket. The gasket allowed
for sharp transition of AF647 positive immunoreactive
tumor areas to unstained areas under or outside the
rubber sealing that present only nuclear counterstain-
ing due to addition of DAPI to the final mounting
solution (Additional file 1: Figure S3).
MTP-based IF staining allows for short antibody
incubation times
Pan-cytokeratin (pan-CK) is widely used in diagnostic
pathology to identify tumor epithelial cells. As the lung
adenocarcinoma samples used in this study are of
epithelial origin, the first test performed with the MTP de-
vice was a direct IF for pan-CK as a positive control stain-
ing. Pan-CK was specifically and rapidly detected in the
cytoplasm of epithelial cells (Additional file 1: Figure S4).
In order to define the optimum primary antibody incuba-
tion time for ALK, serial sections of lung adenocarcinomas
were incubated with anti-human ALK antibody clone 5A4
for 2, 4, 8, 16, or 32 min (Fig. 2a, lower panels), while the
incubation time of the secondary antibody was kept con-
stant at 8 min. For each condition a respective negative
control was performed; no ALK specific signal was found
in the negative controls (Fig. 2a, upper panels). As shown
on the images and the plot, a strong signal intensity for
ALK protein in the cytosol of tumor epithelia was reached
already after 4 min of primary antibody incubation. Longer
primary antibody incubations did not lead to a further
increase of signal intensity (Fig. 2b). We noted a good sep-
aration between ALK specific signal on tumor epithelia and
stromal background.
Tumor epithelia-associated ALK staining on lung
adenocarcinoma cases
A comparison of the relative signal intensity for the
microfluidic-based ALK IF between areas of tumor epi-
thelia and adjacent stroma in three representative cases
Fig. 2 Determination of optimal ALK primary antibody incubation time. a Tissue cuts (Case N°12) were incubated for 2, 4, 8, 16, or 32 min either
with PBST 0.05% (CTL NEG, first row) or the anti-human ALK antibody (ALK, second row). The incubation time of the secondary antibody was kept
constant at 8 min. The same region of interest (ROI) is presented for ALK IF and its negative control. Scale bar is 10 μm. b Quantification of the
ALK stained slides shown in (a). For each incubation time, 25 ROIs were manually placed in areas of ALK+ tumor epithelia and in areas of stroma
only. The graph shows the average of the mean intensities of all 25 ROIs for ALK+ tumor epithelia (blue) and stroma (orange) with corresponding
standard deviations
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of lung ADC is shown Fig. 3a-c. In all 12 surgical speci-
mens, the ALK specific signal was detected on tumor
epithelia above the stromal background intensity
(Fig. 3d). The ALK IF expression was also visually
compared to the corresponding chromogenic IHC for
each case, showing matching regions of ALK positivity
(see Additional file 1: Figure S5 for a representative case).
The same MTP-based ALK IF protocol was used for a
NSCLC TMA. Five lung ADC tumor cores are shown, in-
cluding one ALK-positive and four ALK-negative cases, as
Fig. 3 Variation of ALK immunoreactivity in a series of 12 lung adenocarcinomas. Three representative cases of microfluidic-based ALK IF (MTP IF
ALK) are shown in a Case N°10, b Case N°7 and c Case N°3. Scale bars are 100 μm and 10 μm for the first and second column, respectively. The
third column represents the negative control (CTL NEG) where PBST 0.05% was used instead of the primary antibody. The shown region of
interest for the negative control is the same as for ALK IF; scale bar is 10 μm. d Quantification of the ALK IF signals. For each case, 25 ROIs were
manually placed in both ALK+ tumor epithelia and stroma regions. The graph shows the average of the mean intensities of all 25 ROIs for tumor
epithelia (blue) and stroma (orange) with corresponding standard deviations. Case N°11 is present twice (11#1 and 11#2) as two samples with
distinct localization (lung primary and parietal pleura, respectively) were obtained from the same patient
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assessed by IHC (Fig. 4a). Compared to the ALK-positive
core, no specific ALK signal was detectable in the tumor
epithelia of the four negative cases; as reported earl-
ier, un-specific signal was detectable in the stromal
compartment, like the intra-alveolar macrophages
(Fig. 4b-d).
Correlation of IF values with chromogenic IHC and break-
apart FISH
A threshold H-score value of 120 was previously defined
for ALK positivity [11, 12]; the ALK+ cases included in
this study had a chromogenic ALK immunoreactivity of
H-score ≥ 120 up to 300 (Additional file 2: Table S1). All
Fig. 4 ALK MTP-IF on five lung ADC from a NSCLC TMA. a Shown are five tumor cores including one ALK-positive case next to four ALK-negative cases
(left to right) as assessed by chromogenic IHC; the black coloration visible on the fourth core is anthracosis. The same cores as in (a) have been stained
for ALK by MTP-based IF (b-d) employing the same protocol as for the ALK-positive ADC cases in Fig. 3. Scale bar 100 μm (a-b), 50 μm (c) and 10 μm (d)
Fig. 5 Correlation of the ALK MTP-IF values with chromogenic IHC. Graphical visualisation of the “H-score” (blue) and “MTP-IF” (orange) values for
ALK staining on 12 ALK-positive lung ADC. Sample 11#1 and 11#2 represent two specimens with distinct localization (lung primary and parietal
pleura, respectively) from the same patient (Case N°11)
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12 ALK+ samples analysed by MTP-IF were concordant
with chromogenic IHC. Chromogenic IHC of ALK+
cases showed a variation of 2.5-fold regarding H-score
level (120 to 300). Interestingly, a similar dynamic range
with 2.8-fold variation was found for MTP-IF mean in-
tensity levels (458 to 1301) (Fig. 5). When correlating
these values, we found a nearly statistical significance for
chromogenic IHC with MTP-IF (p-value 0.051) but not
with FISH (p-values > 0.2).
For case N°4, the ALK status was discordantly assessed
by IHC (positive: H-Score 300) and FISH (negative:
break apart found in 10% of tumor cells). This same case
showed an opposite trend when comparing microfluidic
IF with IHC results: although exerting the highest score
by IHC, it resulted in the lowest mean intensity of the
whole series by MTP-IF (value = 458), thus better correl-
ating with the negative FISH result than the H-score.
Discussion
In this study, we have used the novel technology of
microfluidic-based immunofluorescence for the assess-
ment of ALK status in lung adenocarcinoma patients,
using FFPE tumor tissue whole sections from surgical
specimens. We were able to detect specific ALK immu-
noreactivity on tumor epithelia of lung adenocarcinoma
in a fast, reliable, and automated manner, confirming the
IHC results obtained by routinely used staining
procedures.
In some area of the tissue, the non-specific signal of
the 5A4 antibody was present in the stroma on both
IHC and IF stainings. The non-specific activity of the
5A4 antibody is well documented by the supplier as a
diffuse appearance, but also sporadic staining of con-
nective tissue, fibroblasts, necrotic/degenerated cells or
alveolar macrophages.
The ALK staining resulting from the protocol devel-
oped in IF correlates with the one performed by stand-
ard IHC. Firstly, visual comparison of the same region of
interest between IHC and IF, showed the same foci of
heterogeneous ALK expression between the two tech-
niques. Secondly, the computerized analyses of the
tumor specific ALK signal obtained with the MTP-IF
correlated with the H-score values attributed to the IHC
stainings.
Sample nr. 4 was the only case where the correlation
between H-score and MTP-IF did not follow the same
trend: although scored with the highest mark by IHC, it
exerted the lowest score by MTP-IF. Interestingly, it was
scored as negative by ALK break-apart FISH. Further-
more, ALK status for the same sample was assessed by
HTG EdgeSeq ALKPlus assay, an in vitro diagnostic
NGS-based assay intended to measure mRNA ALK gene
fusion events in FFPE NSCLC specimens. Remarkably,
ALK rearrangement status was reported to be negative
(data not shown), suggesting a closer correlation of
MTP-IF to FISH and NGS results as compared to IHC
for this peculiar case.
Alternative to binary scoring, an intensity-based qua-
ternary scoring system (0–3+) was suggested for ALK
IHC, similarly to HER2 (human epidermal growth factor
receptor 2) diagnostic test in breast cancer [13, 14]. Al-
though high correlation was reported for ALK FISH and
IHC (5A4) scored as 0–1+ (FISH-negative) and 3+
(FISH-positive), the 2+ scored cases were variable with
equal repartition in FISH-positive and negative [15]. We
previously showed the MTP-based HER2 staining to
allow for better positive/negative separation among the 2
+ ambiguous cases as assessed by the FISH [7, 8]. In a
similar manner, the ALK MTP-IF may better correlate
with the ALK status as assessed by FISH. Testing of such
hypothesis will require further investigation.
Microfluidics is a powerful novel technology in the
field of tissue diagnosis [16–18], but only a few instru-
ments are commercially available. The fast-fluidic ex-
change (FFEX) technology within the MTP device allows
for a rapid and controlled exchange of reagents while ex-
posing the tissue surface uniformly to the reagents. This
allows the primary antibody to rapidly reach its epitope
on the targeted protein and to be detected by the
secondary antibody. In this study, using the MTP tech-
nology, we show that the signal of ALK IF saturates after
4 min of primary antibody incubation. The reaction
taking place in the MTP chamber is highly controlled,
and the borders limiting the tissue area exposed to the
reagents can be visualised if the tissue is present inside
and outside of the chamber. The gasket that allows the
closing of the chamber delimits the reagent distribution
and thus serves as an internal control for staining quality
and tissue auto-fluorescence. Moreover, we have
addressed the issue of auto-fluorescent lung structures
by analyzing specific immunofluorescent ALK signals on
tumor epithelia and on adjacent stroma on multiple in-
dividual frames laid over the tumoral structures on
whole sections.
One further advantage of the MTP device is its
open-system design, meaning that any kind of reagents
compatible with the internal surfaces of device can be
used. E.g. ALK immunoreactivity could be visualized by
two techniques of detection: [1] a direct staining method
using a secondary antibody labelled with the fluorophore
AF647; [2] an amplification-based staining method,
where the HRP-conjugated secondary antibody catalyses
a fluorescent (AF647) tyramide-based signal amplifica-
tion (TSA). Direct immunofluorescence has the advantage
of being potentially quantitative due to direct probing of
the epitope-specific antibody by secondary IgG coupled to
a fluorophore, while having the disadvantage of generally
low signal to noise ratio due to lack of amplification steps.
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Nevertheless, both detection systems gave a specific and
strong ALK signal.
Of particular interest is the question of how diagnostic,
predictive oncogenic and immune-therapy related markers
are correlated among each other in relation to topographical
proximity and tumor heterogeneity, respectively. Research
has therefore focused on implementation of multiplexed im-
munofluorescence methods, using e.g. the TSA technology.
A multi-parametric immunofluorescence study including
ALK, CD8, PD-1 and PD-L1 was recently performed. In
comparison to EGFR-mutated or WT lung adenocarcin-
omas, ALK-positive tumors had a higher expression of
PD-L1 and a higher number of intra-tumoral CD8+ T cells
or PD-1+ CD8+ Tcells [19].
Therefore, rapid ALK immunofluorescence allowing
for combined detection of multiple markers is likely to
be highly exploited in a near future.
Conclusions
In summary, we report here the first MTP-based IF
protocol for assessment of ALK protein expression in
FFPE tumor tissue of lung adenocarcinoma patients. We
foresee that this study is a first step that opens the road
for further development of microfluidic-based assays to
rapidly detect multiple markers in their topographical
context to better understand tumour heterogeneity and
micro-environmental interactions to advance in targeted
cancer therapy.
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